ReceptorBio, Inc. is an early stage biopharmaceutical company located in Foster City, CA with plans to develop orally active pharmaceuticals for the treatment of T2D and related diseases including obesity, and the insulin resistance/metabolic syndrome which has been associated with a markedly increased risk of cardiovascular disease. The Company's initial focus will be on the clinical development of its lead compound, RB101, believed to activate the insulin receptor tyrosine kinase (IRTK), a recognized drug target for T2D. IRTK activation is one of the early signaling events required to mediate insulin's physiologically effects on glycemic control. Currently, there are no FDA-approved drugs that have this mechanism of action. ReceptorBio believes its novel agents are thus positioned to be first in their class, with a mechanism of action that may be compatible for use both as a single agent and in combination with existing medications for T2D.
The founders and management team of ReceptorBio have a long and
successful history of accomplishments in T2D research and drug development.
Joseph L. Evans, Ph.D., ReceptorBio President, has over twenty years
experience in the research, development, and pharmacology of therapeutics
for T2D and obesity, including positions of increasing responsibility in
drug discovery and development at Sandoz (now Novartis), Shaman, SUGEN,
Telik, and Leptogen. David Klonoff, M.D., FACP, ReceptorBio Director and
Chairman of the Clinical Advisory Board, is a Clinical Professor of
Medicine at the University of California, San Francisco. In addition, Dr.
Klonoff is Medical Director of the Dorothy L. and
|SOURCE ReceptorBio, Inc.|
Copyright©2008 PR Newswire.
All rights reserved